This article is more than 5 years old. Information may no longer be current.
Preoperative mitomycin-C decreased risk for non-muscle invasive bladder cancer recurrence
Click Here to Manage Email Alerts
A single treatment with preoperative intravesical electromotive instillation of mitomycin-C decreased the risk for non-muscle invasive bladder cancer recurrence and improved DFS when compared with early post-transurethal resection intravesical passive diffusion mitomycin-C instillation or transurethal resection alone, new research suggests.
Researchers from Italy randomly assigned 352 patients with non-muscle invasive bladder cancer to one of three treatment groups: immediate preoperative intravesical electromotive instillation of mitomycin-C; early post-transurethal resection intravesical passive diffusion mitomycin-C; or transurethal resection alone.
After 85.4 months follow-up, cancer recurrence was significantly decreased for those in the preoperative intravesical electromotive instillation of mitomycin-C group.
This was also true for median DFS intervals: DFS was 12.9 months for the transurethal resection-alone group; 16.4 months for the early postoperative intravesical passive diffusion of mitomycin-C instillation post-transurethal resection group; and 56.9 months for the pretransurethal resection intravesical electromotive of mitomycin-C instillation pretransurethal resection group.
“Catching bladder cancer before it invades the muscle is key to a patient’s survival,” Kevin T. McVary, MD, associate professor of urology at Northwestern University, Feinberg School of Medicine, said during a press conference. “But even with early detection, this paper demonstrates that recurrence rates can be reduced by preoperative intravesical [preoperative intravesical electromotive instillation of mitomycin-C]. Knowing that a preoperative dose of mitomycin-C can help improve that survival is extremely important.”
For more information:
- Distasi S. #1346.